Sodium ascorbate [134-03-2]

Cat# orb1222741-500mg

Size : 500mg

Brand : Biorbyt


Sodium ascorbate

SKU: orb1222741

Description

Ascorbate, also known as Ascorbicin, is a DNase I inhibitor. Ascorbate is an antioxidant which functions as a reducing agent and coenzyme in several metabolic pathways.(In Vitro):The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5,000.(In Vivo):Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs.After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.

Images & Validation

Key Properties

CAS Number134-03-2
MW201.13
Purity>98% (HPLC)
FormulaC6H8O6·Na
SMILES[Na].05[C@@]1(OC(=O)C(O)C1O)[C@@H](O)CO
Target5-HT Receptor
SolubilityH2O : ≥ 41 mg/mL; 206.96 mM

Bioactivity

In Vivo
Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs. After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats.
In Vitro
The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5, 000.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Ascorbate | Sodium Ascorbate | Vitamin C sodium

Protocol Information